Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.68 |
| ▸ | GSK3B | P49841 | 10/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954192 | 0.91 | CDK2 (0.70) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL12953627 | 0.90 | GSK3B (0.70) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13305588 | 0.88 | CDK2 (0.72) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL12954177 | 0.86 | CDK2 (0.73) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13289265 | 0.86 | CDK2 (0.72) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13122665 | 0.85 | CDK2 (0.71) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13117976 | 0.84 | CDK2 (0.67) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13122670 | 0.84 | CDK2 (0.78) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14598810 | 0.83 | CDK2 (0.66) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13121757 | 0.82 | CDK2 (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130570-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |